


Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination



**Report of the Consultative Expert Working Group on Research
and Development: Financing and Coordination**



**World Health
Organization**

Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination

**Report of the Consultative Expert Working Group on Research
and Development: Financing and Coordination**

April 2012



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

Research and development to meet health needs in developing countries: strengthening global financing and coordination: report of the consultative expert working group on research and development: financing and coordination.

1.Research – economics. 2.Research support. 3.Development. 4.Financing, Health. 5.Developing countries. I.World Health Organization.

ISBN 978 92 4 150345 7

(NLM classification: QW 520)

© **World Health Organization 2012**

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Design by Inis Communication – www.iniscommunication.com

Printed in Italy

Contents

Preface	1
Members of the CEWG	3
Terms of reference	5
Executive summary	8
Chapter 1: Introduction	17
Origins	17
Our approach	19
Outline of the report	22
Chapter 2: Setting the scene: the issues	24
The need for action	24
Trends in R&D in the pharmaceutical industry	27
Research and development relevant to developing countries	32
<i>Expenditure Estimates and Sources of Funding</i>	32
<i>Research Outcomes</i>	35
Research and development and access	37
Research and development financing	38
Research and development coordination	41
Chapter 3: Review of proposals	48
Criteria and method of assessment	48
Mechanisms assessed	49
Summary of assessments	52

<i>Global framework on research and development</i>	53
<i>Removal of data exclusivity</i>	54
<i>Direct grants to companies</i>	54
<i>Green intellectual property</i>	55
<i>Health Impact Fund</i>	55
<i>Orphan drug legislation</i>	56
<i>Patent pools</i>	57
<i>Pooled funds</i>	57
<i>Open approaches to research and development and innovation</i>	58
<i>Milestone prizes and end prizes</i>	58
<i>Purchase or procurement agreements</i>	59
<i>Priority review voucher</i>	60
<i>Regulatory harmonization</i>	60
<i>Tax breaks for companies</i>	60
<i>Transferable intellectual property rights</i>	61
Regional perspectives	62
Conclusions	62

Chapter 4: Strengthening global financing of health research and development

Introduction	64
Sources of finance: proposals assessed by the EWG	64
<i>New donor funds for health research and development</i>	65
<i>Taxation of repatriated pharmaceutical industry profits</i>	66
<i>Voluntary contributions from businesses and consumers</i>	66
<i>A new indirect tax</i>	68
Tax options	69
<i>National taxes</i>	71
<i>Taxes for global purposes</i>	72
<i>Conclusion: tax options</i>	75
Global health research and development: goals and targets	75
<i>Target: 15% of government expenditure to health in Africa</i>	78
<i>Target: 2% of national health expenditure on research and development</i>	79
<i>Target: 5% of development assistance for health to health research</i>	80
<i>Meeting funding needs for R&D</i>	82
<i>Conclusion: health research and development: goals and targets</i>	84

Chapter 5: Strengthening global coordination in health research and development	88
The current landscape of coordination	88
<i>History of coordination efforts</i>	89
<i>The role of WHO</i>	91
<i>Advisory Committee on Health Research</i>	92
<i>Special Programme for Research and Training in Tropical Diseases (TDR)</i>	93
<i>WHO International Clinical Trials Registry</i>	95
<i>WHO research strategy</i>	95
<i>Other initiatives</i>	96
Towards better coordination	97
<i>Objectives of coordination</i>	97
<i>Coordination and funding</i>	98
Conclusions	101
Chapter 6: Implementation: a binding instrument	107
Introduction	107
Proposals assessed by the EWG: sources of finance	107
Other proposals assessed by the EWG	108
CEWG recommendations	110
<i>Approaches to research and development</i>	110
<i>Funding mechanisms</i>	110
<i>Pooling resources</i>	111
<i>Strengthening research and development capacity and technology transfer</i>	111
<i>Coordination</i>	112
Implementation: a new way forward	112
<i>General use of conventions</i>	114
<i>Hard and soft law</i>	118
A binding instrument on health research and development	120
<i>Relevant WHO provisions</i>	120
<i>Elements of a binding agreement</i>	122
Next steps	124

Annex 1: Inception report	127
Annex 2: Mapping of EWG and CEWG processes	131
Summary	131
The EWG's grouping of R&D financing and coordination proposals	132
<i>The first step: creation of an inventory of 109 proposals</i>	<i>132</i>
<i>The second step: from 109 proposals to 91 proposals</i>	<i>132</i>
<i>The third step: from 91 to 22 grouped proposals</i>	<i>133</i>
CEWG grouping of R&D financing and coordination proposals	134
<i>The inventory of R&D financing and coordination proposals considered by CEWG</i>	<i>134</i>
<i>The new landscape of proposals: 15 assessments and chapters on financing and coordination</i>	<i>138</i>
Annex 3: Assessments of proposals	142
Global Framework on Research and Development	142
Removal of data exclusivity	152
Direct grants to companies	155
Green intellectual property	158
Health Impact Fund	160
Orphan drug legislation	165
Patent pools	169
Pooled funds	176
Open approaches to research and development and innovation	182
Milestone prizes and end prizes	190
Purchase or procurement agreements	197
Priority review voucher	200
Regulatory harmonization	204
Tax breaks for companies	208

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28588

